HepaRegeniX initiates a preclinical collaboration with the Netherlands Cancer Institute to explore the potential of its 2nd MKK4 inhibitor HRX-0233 for use in cancer combination therapy • MC Services corporate website
20 Oct HepaRegeniX initiates a preclinical collaboration with the Netherlands Cancer Institute to explore the potential of its 2nd MKK4 inhibitor HRX-0233 for use in cancer combination therapy